1.68
1.68 (0%)
As of Apr 17, 2025
Humacyte, Inc. [HUMA]
Source:
Company Overview
Humacyte, Inc. is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine.
| Country | United States |
| Headquarters | durham, north carolina |
| Phone Number | 919-313-9633 |
| Industry | |
| CEO | Laura E. Niklason, M.D., Ph.D. |
| Website | www.humacyte.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-29.5 |
| Net Income | $-56.7 |
| Net Cash | $13.1 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -82% |
| Profit as % of Stockholder Equity | 200.3% |
Management Effectiveness
| Return on Equity | 200.3% |
| Return on Assets | -41% |
| Turnover Ratio | |
| EBITA | $-29.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $138.3 |
| Total Liabilities | $166.6 |
| Operating Cash Flow | $-48.6 |
| Investing Cash Flow | $-0.6 |
| Financing Cash Flow | $62.3 |
